Covaxin Pharmaceutical: Net profit in 2025 is 159 million yuan, an increase of 406.47% year-on-year.

Kexing Pharmaceuticals released its interim performance report, achieving a total operating revenue of 1.541 billion yuan in 2025, a year-on-year increase of 9.54%; net profit of 159 million yuan, a year-on-year increase of 406.47%. In 2025, the company actively explored overseas markets, achieving strong growth in overseas revenue, driving continuous growth in operating revenue, and significant increase in net profit attributable to owners of the parent company and net profit after deducting non-recurring gains and losses compared to the same period of the previous year.